1. Home
  2. RRX vs TGTX Comparison

RRX vs TGTX Comparison

Compare RRX & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Regal Rexnord Corporation

RRX

Regal Rexnord Corporation

N/A

Current Price

$175.86

Market Cap

10.0B

Sector

N/A

ML Signal

N/A

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

N/A

Current Price

$64.33

Market Cap

8.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RRX
TGTX
Founded
1955
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.0B
8.5B
IPO Year
1994
2008

Fundamental Metrics

Financial Performance
Metric
RRX
TGTX
Price
$175.86
$64.33
Analyst Decision
Strong Buy
Buy
Analyst Count
11
7
Target Price
★ $232.20
$77.50
AVG Volume (30 Days)
1.2M
★ 1.9M
Earning Date
11-03-2026
11-09-2026
Dividend Yield
★ 0.78%
N/A
EPS Growth
42.86
★ 1746.67
EPS
★ 2.52
0.52
Revenue
★ $3,257,100,000.00
$2,785,000.00
Revenue This Year
$4.75
$61.95
Revenue Next Year
$12.95
$35.55
P/E Ratio
★ $71.67
$124.76
Revenue Growth
★ 5.21
N/A
52 Week Low
$127.96
$26.76
52 Week High
$247.80
$68.03

Technical Indicators

Market Signals
Indicator
RRX
TGTX
Relative Strength Index (RSI) 56.37 64.72
Support Level $148.19 $51.70
Resistance Level $221.59 N/A
Average True Range (ATR) 9.12 3.49
MACD 1.81 0.65
Stochastic Oscillator 64.06 73.78

Price Performance

Historical Comparison
RRX
TGTX

About RRX Regal Rexnord Corporation

Regal Rexnord Corp is in the engineering and manufacturing of industrial powertrain solutions, power transmission components, electric motors, electronic controls, air-moving products, and specialty electrical components and systems, serving customers around the world. The three operating segments include Automation & Motion Control (AMC) segment; Industrial Powertrain Solutions (IPS) segment, which derives maximum revenue; and Power Efficiency Solutions (PES) segment. Geographically, the company operates in North America, Europe, Asia, and Rest of the world, of which it derives maximum revenue from North America.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: